A novel long non-coding RNA-KAT7 is low expressed in colorectal cancer and acts as a tumor suppressor

Qingmei Wang1,2†, Rongzhang He1,3†, Tan Tan1,2†, Jia Li1, Zheng Hu1, Weihao Luo1, Lili Duan1, Wenna Luo1 and Dixian Luo1,2*

Abstract

Background: The abnormal expression of many long non-coding RNAs (lncRNAs) has been reported in the progression of various tumors. However, the potential biological roles and regulatory mechanisms of long non-coding RNAs in the development of colorectal cancer (CRC) have not yet been fully elucidated. Therefore, it is crucial to identify that lncRNAs can be used for the clinical prevention and treatment of CRC.

Methods: In our previous work, we identified a novel lncRNA, lncRNA-KAT7, and found that the expression of lncRNA-KAT7 in CRC tissues was significantly lower than that in matched normal intestinal tissues, and the expression in CRC cell lines was lower than that of normal intestinal epithelial cells (P < 0.05). Besides, the expression of lncRNA-KAT7 is negative associated with age, tumor size, tumor differentiation, lymph node metastasis of CRC patients. The potential biological effects and molecular mechanisms of lncRNA-KAT7 in CRC were evaluated using a series of CCK-8 assay, clone formation assay, EdU proliferation assay, scratch determination, transwell determination, western blot analysis, and nude subcutaneous tumorigenesis model construction cell and animal experiments.

Results: The expression of lncRNA-KAT7 in CRC tissues was lower than that in matched normal tissues and normal intestinal epithelial cells (P < 0.05). Decreased expression of lncRNA-KAT7 is associated with clinicopathological features of poor CRC patients. In vitro experiments showed that up-regulation of lncRNA-KAT7 expression in CRC cells inhibited cell proliferation and migration. In vivo animal experiments showed that the lncRNA-KAT7 also inhibited tumor growth. Western blot analysis showed that the expression of lncRNA-KAT7 was up-regulated in HCT116 cells, the expression of E-cadherin increased, and the expression of Vimentin, MMP-2 and β-catenin protein was down-regulated so did the phosphorylation NF-κB P65. The results confirm that the expression of lncRNA-KAT7 can inhibit the malignant phenotype of CRC cells.

Conclusions: Up to now, as a novel lncRNA, lncRNA-KAT7 has not any relevant research and reports. The results confirm that the expression of lncRNA-KAT7 can inhibit the malignant phenotype of CRC cells. And it can be used as a new diagnostic biomarker and therapeutic target for the development of CRC.

Keywords: lncRNA-KAT7, Colorectal cancer, Proliferation, Invasion, Migration, Tumor suppressor

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Colorectal cancer (CRC) is the leading cause of cancer mortality in all humans, with approximately 65% of 5-year survival rate of CRC patients [1]. In recent years, the incidence of CRC is on the rise, showing a trend of younger age. It is still the focus of global health concerns [2]. The specific pathogenesis for CRC remains unclear. It has been reported that many oncogenes and tumor suppressors are involved in the development of CRC [3]. In the past decade, although the popularity of early CRC screening and the continuous advancement of CRC diagnosis and treatment, the mortality rate of CRC has declined [4]. However, the mortality rate for patients with CRC metastasis remains high, and metastasis is still one of the key factors causing low clinical efficacy, poor survival period, and poor prognosis in CRC patients [5]. Therefore, the prevalence and poor outcome of CRC prompted us to reveal the pathological mechanism of CRC progression and to find effective biomarkers for diagnosis and prognosis.

In recent years, a large amount of evidence suggests that long non-coding RNA (lncRNA) has become an indispensable participant in the development of different human tumors [6]. Most of human genome is transcribed into RNA, but only about 2% of RNA encodes proteins. RNAs lacking protein-coding capacity and open reading frame (ORF) are referred to as non-coding RNAs (ncRNAs) and are divided into small ncRNAs and long ncRNAs (lncRNAs) groups [7, 8]. More and more lncRNAs have been found to participate in different physiological and pathological processes in the body, but the vast majority of their functions are still unclear [9]. LncRNAs are non-coding transcripts of 200 nucleotides or more, and most of which are located in nuclear. They have no ORF that results in the loss of translation capacity and emerges as essential regulators of cell growth and tumor metastasis [10]. Many lncRNAs are expressed at low levels and show tissue and cell type-specific expression patterns, whereas the abnormal expression of lncRNAs is attributed to the pathogenesis of some malignant tumors including CRC [11]. It has been reported in the literature that lncRNA has been identified as an oncogene, anti-oncogene and prognostic predictor [12].

Only a few discovered lncRNAs play a key role in different biological processes [13]. The abnormal expression of multiple lncRNAs is associated with CRC, suggesting that lncRNA plays an important role in the development of CRC. Some lncRNA, such as H19, HOTAIR, MALAT1, CCAT2 expressed highly in CRC, are responsible for cell proliferation, migration, and invasion of CRC [14]. In addition, Ye et al. [15] found that a novel lnc-GNAT1-1 is low-expressed in CRC and acts as a tumor suppressor by regulating the RKIP-NF-κB-Snail pathway. Miao et al. [16] found that FOXF1-AS1 affects tumor metastasis by regulating the expression of E-cadherin and Vimentin in non-small cell lung cancer. Recently, lncRNA has become one of the research hotspots, and lncRNA plays a role in oncogenes and tumor suppressor genes in various biological processes such as epigenetic regulation, transcription and translation regulation, splicing, imprinting, cell development, metastasis, and apoptosis [17]. One of the most critical steps in the tumor cell metastasis cascade is to gain invasive capabilities, including disrupting cell–cell connections, degrading the cell matrix, and activating pathways that control the cytoskeleton dynamics. EMT is a key factor in biological processes. Epithelial cells lose their polarity and convert to a mesenchymal phenotype that causes the metastasis of cancer cells [17–21]. EMT enhances the invasion of cancer cells, in response to environmental triggers, strengthens invasive functions, and also conduces to cell growth and survival [22]. In addition, the literature also confirms that many lncRNAs promote or inhibit the occurrence and progression of tumors by modulating the EMT pathway [23].

To investigate the role of lncRNAs in CRC, we performed lncRNA microarray assays using “Agilent All-Human Genome Oligonucleotide Microarray (4×44 K)” (Bohai Biotechnology, Shanghai, China) according to the standard protocol of the expression profiling microarray. Three pairs of CRC normal tissues and tumor tissues were tested. It was found that lncRNA-KAT7 was significantly lower expressed in CRC tumor tissues than that in normal tissues compared with normal intestinal epithelial tissues in differentially expressed lncRNAs. KAT7 is an lncRNA located on the human chromosome 17, plus the hg19 region, which contains 575 transcripts without 5’ cap structure3’ polyadenylation tail (Fig. 1a, b), Kozak sequence or ORF, and with a PhyloSCF score of 342 (Fig. 1c). Biopredictive software suggests that lncRNA-KAT7 does not have protein coding capability. LncRNA-KAT7 was significantly decreased in CRC tumor tissues, indicating that lncRNA-KAT7 may be involved in tumorigenesis and progression of CRC.

To the best of our knowledge, there is no relevant reports on lncRNA-KAT7 in CRC. Therefore, the purpose of this study was to determine the expression and biological effects of lncRNA-KAT7 in CRC in the cellular, animal level and human specimens, especially its role in the metastasis of CRC tumors. This study provides important clues for finding new CRC biomarkers and preventing and treating targets.

Materials and methods

Patients and samples

This study included 140 patients with CRC diagnosed in the First People’s Hospital of Chenzhou City between 2014 and 2016. Fresh colorectal neoplasms and matching
a **TRANSCRIPT:LNC-KAT7-4:1**

**Basic information**
LNCipedia transcript ID: Inc-KAT7-4:1
LNCipedia gene ID: Inc-KAT7-4
Location(hg19):chr17:47785696-47797422
Strand: +
Class: antisense
Transcript size: 575 bp
Exons: 2

---

b

| 1   | TTCTACGCTC TTGAAAGCTT TCAGCCGCCG AGCGAACCAG CGCAAGGCTG TCGTGAAGTC  |
| 61  | TTACACGCAG GACTCAACCC GTGATCCCAG GGCACGCAA CATAAGAGAC TATAGGCTAT  |
| 121 | TCTACCGGTA CGACTGTTG CAAGAAGAAC GAGCTCGTGTG ACTGTATCAT TTTAAGCTAG |
| 181 | ACACGGCCGG GTATAGGCTA ACACGGAGA ATCCGCTTT TTTCAGGCCC CATCAGTTAT  |
| 241 | GGGCTTGATA GACGCCGCGC GTGAGCTTCT TCGCGCTGTA CCAGACAAAG GCGCCGGCGA |
| 301 | CCAAGCTCCAC CACATAAGAC CCACGAAGGA TCAGAGCAAC CGCTAACACC CTTTATCTG  |
| 361 | CTGTCGCGCT GCTCCGCAAT TGAAGAAGCT GCAGCCTCT ATATTTCCC AAAACTACA  |
| 421 | GAAACCGCAAG CCTCGAGTTCC GATAACCTGA TTGTCGAGAA GTAATCTGT TTGTGTCTC  |
| 481 | GTCAGTCATC TAAGGTGGGG CGCCTAGTCG TGCCGCTAGG GCAGCGCTGG CTCAGGGGCC |
| 541 | AAGGGTGGCCT ATGTAAACCT AGACGGCCCA GCAGCC |

c **Protein coding potential**

| Metric                              | Raw result | Interpretation   |
|-------------------------------------|------------|------------------|
| PRIDE reprocessing 2.0              | 0          | non-coding 2     |
| Lee translation initiation sites    | 0          | non-coding 2     |
| PhyloCSF score                      | -341.949   | non-coding 2     |
| CPAT coding probability             | 13.62%     | non-coding 2     |
| Bazzini small ORFs                  | 0          | non-coding 2     |

---

d

![Graph showing relative expression of lncRNA-KAT7](image)

**N=140, p<0.05**

---

e

![Graph showing relative expression of lncRNA-KAT7](image)

**Relative expression of lncRNA-KAT7**

---

f

![Graph showing relative expression of KAT7](image)

**Relative expression of KAT7**

**CCD-18co**

**SW480**

**HCT116**

**LoVo**

**LS174T**

**SW620**

**DLD1**
normal tissues (located > 2 cm away from the tumor boundary) were obtained from 140 patients, and samples should be placed in liquid nitrogen quickly and stored frozen until RNA extraction. All specimens were examined histopathologically and no other treatment had been performed before surgical resection. The clinical characteristics of the patients are shown in Table 1. All experiments in this study were conducted in accordance with guidelines and procedures.

**Cell lines and cell culture**
The normal human colonic tissue cell CCD-18Co and human CRC cell lines HCT116, SW620 were purchased from the Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai, China), human CRC cell lines LoVo and LS174T were donated by Dalian Medical University, and Human CRC cell lines SW480 and DLD1 were donated by Sun Yat-Sen Cancer Center. The cell lines were subcultured and preserved in our lab. The cells were cultured in RPMI 1640 or DMEM (Gibco) medium supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% double antibiotics (penicillin, streptomycin) at 37 °C and under 5% CO2 in a cell incubator.

**RNA extraction and quantitative real-time PCR**
Total RNA was extracted from each cell sample and fresh frozen tissues using Trizol reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. The absorbance ratio at 260/280 nm of the isolated RNA were measured with NanoDrop 2000c spectrophotometer (Thermo Fisher). For IncRNA quantification, GAPDH was used as internal control, and GoScript™ RT System (Promega, USA) were used for quantitative real time reverse transcript PCR (qRT-PCR). The primer sequences were as follows: IncRNA-KAT7 forward: 5′-AGCTCTTGTTGGAGCCCTTC-3′, IncRNA-KAT7 reverse: 5′-GGGCCTGTGTTGATTTTGTC-3′, GAPDH forward: 5′-ACACAGTCTCATGCCATCA-3′, GAPDH reverse: 5′-TCCACCTGTCTGTGA-3′; Axin2 forward: 5′-AGCCAAAGGATCTCAAAAGG-3′, Axin2 reverse 5′-AAGTCAAAAACA TCTGTAGGCA-3′.

Each experiment was performed in triplicate. The fold change for each gene relative to the control group was determined using the 2-ΔΔCT method.

**Vector construction and cell stable transfection**
In order to study the biological effect of IncRNA-KAT7 in CRC, the cDNA sequence of human full-length IncRNA-KAT7 was introduced into the empty vector pcDNA3.1 to construct a recombinant plasmid pcDNA-KAT7. HCT116 and DLD1 cells were then transiently transfected with pcDNA-KAT7 using Lipofectamine®-2000 Reagent (Invitrogen) according to the manufacturer’s instructions. 24 h later, different concentrations of neomycin (G418) were added to the medium of HCT116, DLD1 cells to screen the cells transfected stably with pcDNA-KAT7. Blank control cells and the cells with IncRNA-KAT7 over-expression were named as control, HCT116/pcDNA-3.1, DLD1/pcDNA-3.1, HCT116/pcDNA-KAT7, DLD1/pcDNA-KAT7, respectively.

**Cell proliferation assay**
Log phase cells (5 × 103 cells per well) were seeded in 96-well plates. The cell proliferation was assessed with Cell Counting Kit-8 (CCK8) according to the manufacturer’s instructions. Proliferation rates were determined at 0, 24, 48, 72 and 96 h after transfection by measuring the absorbance. The Cells in each group were tested for 5 replicates. The EDU Cell Proliferation Assay Kit (Green Sky, Shanghai, China) was used to evaluate cell proliferation. At the log phase of cell growth, the cells were spiked with 5-ethynyl-2′-deoxyuridine (EdU) according to the manufacturer’s instructions. Briefly, the cells were incubated with 50 mM EdU for 3 h, and then the cellular nuclei were treated with DAPI staining (Sigma) at a concentration of 1 mg/ml for 10 min, the cell proliferation indexes were photographed and recorded by fluorescence microscopy.

**Clone formation assay**
Cells in the growth phase (300 cells per well) were seeded in 6-well plates, and cultured in cell incubator at 37 °C in 5% CO2 for about 10 days until large colonies were visible. Colony formation was determined by counting the number of visible colonies after being fixed with 4% paraformaldehyde for 15 min and stained with crystal violet dye for 10 min.
Transwell assay
Cell migration and invasion were measured using a Corning polycarbonate film insert transwell chamber (Corning, USA) containing 8 μm pores in the presence or absence of Matrigel (BD Biosciences, USA) according to the manufacturer's protocol. Cells (5 × 10^4 cells per well) were seeded in the upper of chamber for migration assay (without Matrigel) for 24 h, and cells (10 × 10^4 cells per well) were seeded in the upper of chamber for invasion assay (use Matrigel) for 24 h. The medium containing 10% FBS was placed in the lower chamber as an attractant. 24 h later, the cells were fixed in 4% paraformaldehyde for 20 min and then stained with 0.1% crystal violet for 10 min. The cells in the upper chamber were removed with a cotton swab and dried, and the images were captured in 6 random zones under each microscope. The number of cells was counted by Image software. The mean cell count of three independent membranes was defined as the migration or invasion index. The experiment was repeated three times.

Wound healing assay
Cells were cultured in 24-well plate until the cell density reached 80–90% confluence. Then, two vertical wound were scratched using a 100 μl micro tip. The cells were washed twice with phosphate buffered saline (PBS) to remove cell debris and then the cells were cultured in serum-free medium. The images were captured at 0 h, 24 h and 48 h, and the width of the wound was assessed by using Images-Pro Plus software.

Nude subcutaneous tumorigenesis model
6-week-old male athymic BALB/c nude mice were maintained in laminar flow cabinets under specific pathogenic conditions. All animal work was conducted in accordance with national guidelines. All animal experiments were approved by the Ethical Committee of the First People’s Hospital of Chenzhou City, university of South China. Stably transfected cells were washed twice and resuspended in 1 x phosphate buffer. 100 μl of DLD1-pcDNA-3.1 and DLD1-pcDNA-KAT7 (3 × 10^6 cells

---

Table 1 Relationship between KAT7 and clinicopathological characteristics in patients with CRC (N = 140; χ² test)

| Clinicopathological characteristic | Total | LncRNA-KAT7 expression | χ² value | P value |
|-----------------------------------|-------|------------------------|----------|--------|
|                                   |       | High (%) | Low (%) |        |        |
| Age (years)                       |       |          |         |        |        |
| < 60                              | 59    | 27 (45.8) | 32 (54.2) | 0.732 | 0.392 |
| ≥ 60                              | 81    | 43 (53.1) | 38 (46.9) |        |        |
| Sex                               |       |          |         |        |        |
| Male                              | 76    | 41 (53.9) | 35 (46.1) | 1.036 | 0.309 |
| Female                            | 64    | 29 (45.3) | 35 (54.7) |        |        |
| Tumor site                        |       |          |         |        |        |
| Rectum                            | 77    | 45 (58.4) | 32 (41.6) | 4.877 | 0.027 |
| Colon                             | 63    | 25 (39.7) | 38 (60.3) |        |        |
| Tumor size                        |       |          |         |        |        |
| < 5 cm                            | 77    | 46 (59.7) | 31 (40.3) | 6.494 | 0.011 |
| ≥ 5 cm                            | 63    | 24 (38.1) | 39 (61.9) |        |        |
| Tumor differentiation            |       |          |         |        |        |
| Well/moderate                     | 124   | 66 (53.2) | 58 (46.8) | 4.516 | 0.034 |
| Poor                              | 16    | 4 (25)    | 12 (75)   |        |        |
| Depth of invasion                 |       |          |         |        |        |
| T1 + T2                           | 12    | 7 (58.3)  | 5 (41.7)  | 0.365 | 0.546 |
| T3 + T4                           | 128   | 63 (49.2) | 65 (50.8) |        |        |
| Lymph node metastasis             |       |          |         |        |        |
| N0                                | 72    | 42 (58.3) | 30 (41.7) | 4.118 | 0.042 |
| N1/2                              | 68    | 28 (41.2) | 40 (58.8) |        |        |
| TNM stage                         |       |          |         |        |        |
| I+II                              | 68    | 38 (55.9) | 30 (44.1) | 1.830 | 0.176 |
| III+IV                            | 72    | 32 (44.4) | 40 (55.6) |        |        |
| Distant metastasis                |       |          |         |        |        |
| Absence                           | 119   | 61 (51.3) | 58 (48.7) | 0.504 | 0.478 |
| Presence                          | 21    | 9 (42.9)  | 12 (57.1) |        |        |
per mouse) cells suspension were injected subcutaneously into the back of BALB/c athymic mice (n = 6 per group). The size of the tumor was recorded every week with vernier caliper, and the primary tumor growth was calculated from the formula (length × width²)/2 [24]. Four weeks after the injection, the nude mice were sacrificed, and the dorsal tumors were excised and weighed after they had been photographed and measured. Sections from the tumors were stained with hematoxylin and eosin (H & E) for general histology, or immunostained with specific antibodies (anti-Ki67 for proliferation) [25].

Western blot analysis
The expression levels of E-Cadherin, Vimentin, MMP-2, NF-κBp65, p-NF-κBp65, β-catenin, Snail, Twist and ZEB1 proteins were detected by western blot. The total protein was extracted and the protein concentration was measured by BCA method. 40μg proteins were subjected to SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes (PVDF). The membranes were incubated with primary antibodies followed by horseradish peroxidase (HRP)-labeled secondary antibody. Protein bands were detected using the enhanced chemiluminescence with imaging system (Bio-Rad, CA, USA). We used β-actin as a loading control.

Statistical analysis
All data are based on the mean ± standard deviation (SD) from at least three independent experiments. Statistical analysis was performed using SPSS 18.0 software and Graph Pad Prism 6. The relationship between clinicopathological features and Inc-KAT7 expression level was assessed using Chi squared test (χ² test). One-way analysis of variance (ANOVA), paired t test and unpaired t test were used for statistical comparison. All P values were two-sided, and P values < 0.05 were considered significant.

Results
Basic information of IncRNA-KAT7 gene
As described above, we previously performed IncRNA expression microarray analysis using the “Agilent Whole Human Genome Oligonucleotide Microarray (4 × 44 K)” according to a standard protocol to find differential expression IncRNA between CRC tissue and normal colon tissue. A novel IncRNA, IncRNA-KAT7 was screened from the differentially expressed IncRNA transcripts. LncRNA-KAT7 (ENST00000512720.1) is located on the positive strand of hg19 region of human chromosome 17, and the transcript length is 575 base pairs. Bioinformatic software predicts that there is no open reading frame (ORF) and the PhyloSCF score is -342, suggesting that there is no protein coding ability, 5' cap structure or 3' polyA tail of IncRNA-KAT7 (Fig. 1a–c).

LncRNA-KAT7 is low expressed in CRC tissues
The relative expression levels of IncRNA-KAT7 were measured using qRT-PCR in 140 patients with CRC, normalized to GAPDH. LncRNA-KAT7 was down-regulated in 71.4% (100/140) of CRC tissues compared with matched adjacent normal tissues (P < 0.05, Fig. 1d, e). We then evaluated whether IncRNA-KAT7 expression was associated with any clinicopathologic parameters in patients with CRC. The above data were indicated that IncRNA-KAT7 might be involved in the occurrence and progression of CRC. We divided the 140 patients with CRC into a high IncRNA-KAT7 tumor expression group (n = 70) and a low expression group (n = 70) (Table 1). As shown in Table 1, the expression level of IncRNA-KAT7 in cancer tissues was associated with tumor differentiation (P = 0.034), lymph node metastasis (P = 0.042), tumor size (P = 0.011), tumor site (P = 0.027). The above data shows that IncRNA-KAT7 may be involved in the development of CRC.

LncRNA-KAT7 is lowly expressed in CRC cells
The relative expression level of IncRNA-KAT7 in CRC cell lines was further detected in CRC cells (Fig. 1f). Particularly, the expression levels of IncRNA-KAT7 in all 6 CRC cell lines (HCT116, SW620, LoVo, SW480, DLD1 and LS174T) are lower than that in the normal human colon tissue cells (CCD-18Co). The expression level of IncRNA-KAT7 in CRC cells corresponds to the level of histological outcomes. We chose HCT116 and DLD1 with relative low expression level of IncRNA-KAT7, for further study to assess the potential biological function of IncRNA-KAT7 in CRC.

Overexpression of IncRNA-KAT7 inhibited the proliferation, migration and invasion of CRC cells
To elucidate the role of IncRNA-KAT7 in CRC progression, we have up-regulated the expression of IncRNA-KAT7 in HCT116 and DLD1 cells by using stably transfection. HCT116 and DLD1 cells were stably transfected with IncRNA-KAT7 expression plasmid, and the efficiency of IncRNA-KAT7 overexpression was verified by real-time PCR, with the change of approximately 90-fold and 50-fold, respectively (Fig. 2a, b). Our results showed that when IncRNA-KAT7 was overexpressed, the proliferation and colony forming abilities of HCT116 and DLD1 cells were inhibited compared to negative control cells (Fig. 2c–f). In transwell migration and invasion assays, overexpression of IncRNA-KAT7 attenuated the migratory and invasive abilities of HCT116 and DLD1 cells (Fig. 3a, b). In wound healing assays, IncRNA-KAT7
Overexpression reduced the wound healing abilities of HCT116 and DLD1 cells (Fig. 3c, d). The above in vitro experiments performed in the two CRC cell lines suggested that lncRNA-KAT7 overexpression may suppress the malignant phenotypes of CRC cell lines, which was in correspondence with the clinical findings.

**Overexpression of lncRNA-KAT7 inhibited tumor growth in vivo**

To confirm effect of lncRNA-KAT7 on tumor proliferation in vivo, DLD1/pcDNA3.1 and DLD1/pcDNA-KAT7 cells were subcutaneously inoculated into the back of nude mice. Tumor size was measured over time. Mice in the DLD1/pcDNA-KAT7 group developed smaller tumors than those in the DLD1/pcDNA3.1 group (p < 0.01) (Fig. 4a–c). IHC assays confirmed that the Ki-67 proliferation index in the DLD1/pcDNA-KAT7–xenografted tumors was lower than that in DLD1/pcDNA3.1–xenografted tumors (Fig. 4c, d).

**LncRNA-KAT7 regulates the expression of proliferation, invasion and metastasis-associated protein in CRC**

EMT is one of the classical pathways for metastasis of tumor cells, and deletion of E-cadherin and increase of Vimentin are the basic events for the formation of EMT [20–23]. Matrix metalloproteinases MMP-2 promotes the invasion and migration of tumor cells. To further explore the underlying role of lncRNA-KAT7 in CRC cancer biology, we detected the expression of EMT-related proteins by western blot. LncRNA-KAT7 expression increased the expression of E-cadherin in HCT116 cells and decreased the expression of Vimentin, MMP-2 and β-catenin, Twist (Fig. 5a), and did not affect the protein expression of ZEB1 and Snail [20–23].

Wnt/β-catenin and NF-κB signaling pathway play important roles in regulating the proliferation and migration of tumor cells, [26, 27]. Up-regulating of lncRNA-KAT7 attenuated the expression of phosphorylated NF-κB P65 in HCT116 cells (Fig. 5b), and the mRNA expression level of AXIN2, a β-catenin-target gene (Fig. 5c). Therefore, it was suggested that lncRNA-KAT7 can induce the proliferation, migration and invasion by regulating the expression of these proteins.

**Discussion**

Long non-coding RNAs (long ncRNAs, IncRNA) are defined as transcripts longer than 200 nucleotides that are not translated into protein. This somewhat arbitrary limit distinguishes long ncRNAs from small non-coding RNAs such as microRNAs (miRNAs), small interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snRNAs), and other short RNAs. Long intervening/intergenic noncoding RNAs (lincRNAs) are sequences of IncRNA which do not overlap protein-coding genes. Non-coding genomic portion accounts for 90% of mammalian whole genome [13]. LncRNA is a novel functional regulatory element that regulates gene expression and has undergone a transition from “biological waste, noise” to “biologically important regulators” [11]. The abnormal expression of lncRNA in tumors is closely related to the pathogenesis of tumors. However, the number of IncRNAs in CRC is still limited, and the molecular mechanism of the specific role is still not clear. It needs to be further improved. Metastasis results in approximately 90% of cancer-related mortality [28]. Although the mortality rate of CRC has declined in recent years, the prognosis of patients with metastatic CRC remains poor. Studies on IncRNAs in CRC may provide new insights into the development of CRC.
Fig. 4 Over-expressed lncRNA-KAT7 inhibits the growth of CRC cells in vivo. 

a. Up-regulation of lncRNA-KAT7 expression may inhibit the formation of subcutaneous tumor in a nude mouse model. DLD1/pcDNA3.1 and DLD1/pcDNA-KAT7 cells were inoculated subcutaneously on the back of nude mice.

b. DLD1/pcDNA-KAT7 cells were analyzed for the influence of KAT7 on tumor growth and weights in vivo, compared to DLD1/pcDNA3.1 group.

c. Comparison was made between the pcDNA3.1 group and the pcDNA-KAT7 group weekly using t-tests.

d. The tumor sections were subjected to H&E and IHC staining using antibodies against Ki-67 and the Ki-67 index was calculated as the number of Ki-67 positive cells divided by the number of total cells × 100%. Error bars indicate the mean ± SD of 6 different fields. Scale bars = 100 μm. **P < 0.01; ***P < 0.001
LncRNA has become a research hotspot and has attracted great interest from researchers around the world. Many lncRNAs display tissue and cell type-specific expression patterns at low expression levels and play a key regulatory role in biological processes. For example, Ye et al. [15] found that a novel lnc-GNAT1-1 is low-expressed in CRC and acts as a tumor suppressor by regulating the RKIP-NF-κB-Snail pathway. Zhou et al. [29] evaluated the potential of several lncRNAs as diagnostic markers for gastric cancer and finally demonstrated that plasma H19 may serve as a potential diagnostic biomarker for gastric cancer, especially in early-stage patients. It was reported that lncRNA FOXF1-AS1 is a possible cancer suppressor and its expression is decreased in gastric cancer tissues and lung cancer tissues. Miao et al. found that FOXF1-AS1 regulates E-cadherin and Vimentin in tumor metastasis in non-small cell lung cancer. Our previous study data have reported that lncRNA-KAT7 was low expressed in CRC cancer tissues and cells and negatively correlated with poor pathological characteristics of the CRC patients, further supporting this hypothesis.

In vitro cell experiments showed that overexpression of lncRNA-KAT7 inhibited the proliferation, migration and invasion of CRC cells. In addition, to evaluate the effect of lncRNA-KAT7 on the growth of CRC tumors in vivo, we subcutaneously injected DLD1 cells overexpressing KAT7 into the back of nude mice, and the growth of the xenograft primary tumors was monitored. As shown in Fig. 3, xenograft tumors were generated at the injection site 10 days later. During 4 weeks of observation period, tumor growth in the KAT7 group was significantly slower than in the control group. Therefore, the tumor volume of the KAT7 group was significantly smaller than that of the control group. Immunohistochemical staining showed that Ki-67 index was lower in the KAT7 group than that in the control group (Fig. 3d). Low Ki-67 index demonstrated weak cell proliferation [6]. These data indicate that lncRNA-KAT7 plays a key role in the growth of CRC in vivo.

Although the specific mechanisms of lncRNAs involved in cancer biology have not been fully elucidated, a large number of studies have demonstrated that lncRNAs mainly regulate gene expression by interacting with proteins [30]. For example, HOTAIR, which is highly expressed in CRC stem cells, regulates the expression of E-cadherin, Vimentin, and N-cadherin in EMT-related molecules [31]. H19 was proved to be a novel regulator of EMT in CRC cells, interfering with the expression of proteins...
H19 can significantly inhibit the expression of mesenchymal core marker gene vimentin, ZEB1 and ZEB2 in CRC cells [21]. Overexpression of IncRNA MEG3 in CRC can affect MMP-2 and MMP-9 expression to inhibit cell invasion and migration ability [11]. Deletion of E-cadherin and upregulation of vimentin are the basic events for the formation of EMT, which is one of the classical pathways for tumor cell metastasis. In this study, IncRNA-KAT7 significantly promoted the expression of E-cadherin, and inhibited the expression of Vimentin, β-catenin and Twist. Additionally, MMP2, an important factor for cell invasion, was downregulated by IncRNA-KAT7 in CRC. Therefore, IncRNA-KAT7 plays the important role in the migration and invasion by regulating EMT-related genes.

As one of the most studied transcription factors, NF-κB can regulate a variety of cellular processes in cancer, including proliferation, migration and invasion, angiogenesis, and chemotherapy resistance [27, 32]. In this study, IncRNA-KAT overexpression significantly suppressed the phosphorylation of NF-κB p65 in HCT116 cells. The expression of proliferation-related β-catenin was relatively weakened, and so did the expression level of Twist, a Wnt/β-catenin signal-related molecular. These data suggest that IncRNA-KAT7 may inhibit the proliferation and metastasis of CRC cells by modulating the expression of EMT-related proteins through regulating NF-κB signal pathway and Wnt/β-catenin signal pathway.

We have demonstrated that overexpression of IncRNA-KAT7 can inhibit the malignant phenotype of CRC cells, and low expression of IncRNA-KAT7 may lead to a more aggressive CRC cell phenotype. It was confirmed that IncRNA-KAT7 acts as a new IncRNA to inhibit cell proliferation and metastasis in CRC to exert tumor suppressing activity. However, this study also has some shortcomings. It is necessary to further verify the molecular mechanism of IncRNA-KAT7 involving in CRC invasion and metastasis. The in-depth study of these functional experiments and molecular mechanisms will provide new ideas, new strategies and new targets for the diagnosis and treatment of CRC.

**Conclusion**

Generally, we have identified a novel IncRNA, IncRNA-KAT7 is under-expressed in CRC tissues and negatively correlated with tumor differentiation, tumor size, and lymph node metastasis in CRC patients. Up-regulation of IncRNA-KAT7 expression in CRC cells not only inhibited cell proliferation, migration and invasion in vitro, but also inhibited tumor growth in vivo. Therefore IncRNA-KAT7 is likely to exert tumor suppressor activity in the development of CRC. Our findings will provide new biomarkers and therapeutic candidates for CRC.

**Abbreviations**

CRC: colorectal cancer; IncRNAs: long non-coding RNAs; IncRNA-KAT7: long non-coding RNA-KAT7; SNP: single nucleotide polymorphisms; VEGFA: vascular endothelial growth factor A; SFPQ: splicing factor proline and glutamine-rich; RKIP: Raf-kinase inhibitory protein; ZEB1: Zinc finger E-box Binding homeobox 1.

**Author contributions**

DL, RH, TT and ZH designed the experiments. QW, RH, JL, WL, LD, WJ, performed the experiments and analyzed the corresponding results. QW and DL wrote the manuscript. All authors read and approved the final manuscript.

**Author details**

1 Translational Medicine Institute, National & Local Joint Engineering Laboratory for High-throughput Molecular Diagnosis Technology, The First People’s Hospital of Chenzhou, University of South China, Chenzhou 423000, People’s Republic of China. 2 Center for Clinical Pathology, The First People’s Hospital of Chenzhou, University of South China, Chenzhou 423000, People’s Republic of China. 3 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, People’s Republic of China.

**Acknowledgements**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

All the data and material could be traced from the paper or can be requested from the corresponding author.

**Consent for publication**

All the listed authors have participated in the study, and have seen and approved the submitted manuscript.

**Ethics approval and consent to participate**

The study was approved by the local Ethic Committee.

**Funding**

Funding was provided by the Hunan Province Science Fund for Distinguished Young Scholars (2018JJ1021), the Key R&D Program of Hunan Province (2017SK2172), the Natural Science Foundation of Hunan Province (2017JJ2003, 2017JJ2004), the Hunan Province Technological Innovation Guidance Plan, Clinical Medical Technology Innovation Guidance Project (2017SKG1101), the Health Department project of the Hunan Province (B2017182, B20180378, B20180266), the Science and Technique Foundation of Chenzhou (jsyf2017021, jsyf2017023).

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received: 8 December 2018   Accepted: 15 February 2019**

**Published online: 26 February 2019**

**References**

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
2. Eberth JM, Thibault A, Caldwell R, Josey MJ, Qiang B, Pena E, LaFrance D, Berger FG. A statewide program providing colorectal cancer screening to the uninsured of South Carolina. Cancer. 2018;322:672–95.
3. Liu X, Cui L, Hua D. Long non-coding RNA XIST regulates miR-137-EZH2 axis to promote tumor metastasis in colorectal cancer. Oncol Res. 2018;138:225–36.
4. Sun J, Ding C, Yang Z, Liu T, Zhang X, Zhao C, Wang J. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J Transl Med. 2016;14:78–92.
5. Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017;474:4219–51.

6. Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, Lu Y, Zheng L, Zhang W, Li X, Li X. Long non-coding RNA CASC11 interacts with hnRNP K and activates the WNT/beta-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett. 2016;376:62–73.

7. Svoboda M, Slyslova J, Schneiderova M, Makovicky P, Bielik L, Levy M, Lipiska L, Hemmelova B, Kala Z, Protvankova M, Vydral O, Liska V, Schwarzo L, Vodickova L, Vodicka P. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35:1510–5.

8. Kogo R, Shimamura T, Mimosi K, Kaikawa H, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71:6320–6.

9. Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, Jenkins LM, Shabalina SA, Mo M, Dasso M, Yang Y, Wakefield LM, Zhu Y, Frier SM, Moriarty BS, Prasanth KV, Perez-Pinera P, Lal A. Prosurvival long noncoding RNA PVRCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3. eLife. 2017;6:e23244.

10. Li H, Ma SQ, Huang J, Chen XP, Zhou HH. Roles of long noncoding RNAs in colorectal cancer metastasis. Oncotarget. 2017;8:39859–76.

11. Dhamija S, Diederichs S. From junk to master regulators of invasion: IncRNA functions in migration, EMT and metastasis. INT J Cancer. 2016;139:269–80.

12. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:534–61.

13. Jandura A, Krause HM. The new RNA world: growing evidence for long noncoding RNA functionality. Trends Genet. 2017;33:665–76.

14. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stieler V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA. H19 noncoding RNA, an independent prognostic factor, regulates essential Rb-E2F and CDK8-beta-catenin signaling in colorectal cancer. EBioMedicine. 2016;3:6320–6.

15. Ye C, Shen Z, Wang B, Li Y, Li T, Yang Y, Jiang K, Ye T, Wang S. A novel long non-coding RNA Inc-GNAT1-1 is low expressed in colorectal cancer and acts as a tumor suppressor through regulating RIPK-NF-kappaB-Snail circuit. J Exp Clin Cancer Res. 2016;35:187.

16. Miao L, Huang Z, Zengli Z, Li H, Chen Q, Yao C, Cai H, Xiao Y, Xia H, Wang Y. Loss of long noncoding RNA FOXL1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. Oncotarget. 2016;7:68339–49.

17. Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 2014;5:e944014.

18. Tao Y, Han T, Zhang T, Ma C, Sun C. LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway. Oncotarget. 2017;8:36410–22.

19. Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, Peng Z, Yan D. LncRNA-ATB mediated E-cadherin expression promotes the progression of colon cancer and predicts poor prognosis. J Gastroen Hepatol. 2016;31:595–603.

20. Kong J, Sun W, Li C, Wan L, Wang S, Wu Y, Yu E, Zhang H, Lai M. Long non-coding RNA LINCO1113 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. Cancer Lett. 2016;380:476–84.

21. Liang WC, Fu WM, Wong CW, Yang W, Wang SM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, Waye CM. The IncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6:22513–25.

22. Thiery JP, Acloque H, Huang Ry, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.

23. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119:1438–49.

24. Zhang ZY, Lu YX, Zhang ZY, Chang YY, Zheng L, Yuan L, Zhang F, Hu YH, Zhang WJ, Li XN. Loss of TINCR expression promotes proliferation, metastasis through activating EpCAM cleavage in colorectal cancer. Oncotarget. 2016;7:22639–49.

25. Yang MH, Hu ZY, Xu C, Xie LY, Wang XY, Chen SY, Li ZG. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRK A anchor protein 9. Bba-Bioenergrtics. 2015;1852:166–74.

26. Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt/beta-catenin in colon cancer. Expert Opin Ther Targets. 2014;18:611–5.

27. Rinkenbaugh AL, Baldwin AS. The NF-kappaB pathway and cancer stem cells. Cells. 2016:556.

28. de Sousa EMF, Vermeulen L. Wnt signaling in cancer stem cell biology. Cancers (Basel). 2016;8:60.

29. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11516.

30. Li W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, Zhang Y, Liu S, Yang J, Xu B, He L, Sun L, Jiang J, Shang Y. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest. 2017:127:3421–40.

31. Dou J, Yi Y, He X, Wu D, Li M, Wu S, Zhang R, Guo M, Zhao F. Decreasing IncRNA HOTAIR expression inhibits human colorectal cancer stem cells. AM J Transl Res. 2016;8:98–108.

32. Vazquez-Santillan K, Mekendez-Zaglia J, Jimenez-Hernandez L, Martinez-Ruiz G, Maldonado V. NF-kappaB signaling in cancer stem cells: a promising therapeutic target? Cell Oncol. 2015;38:327–39.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions